José M Medina Selected Research

Tolbutamide (Orinase)

11/2010	Inhibition of ATP-sensitive potassium channels increases HSV-tk/GCV bystander effect in U373 human glioma cells by enhancing gap junctional intercellular communication.
8/2006	Tolbutamide reduces glioma cell proliferation by increasing connexin43, which promotes the up-regulation of p21 and p27 and subsequent changes in retinoblastoma phosphorylation.
3/2005	The increase in gap junctional communication decreases the rate of glucose uptake in C6 glioma cells by releasing hexokinase from mitochondria.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

José M Medina Research Topics

Disease

7	Glioma (Gliomas) 08/2021 - 03/2005
3	Alzheimer Disease (Alzheimer's Disease) 01/2018 - 01/2009
3	Hypoxia (Hypoxemia) 01/2012 - 01/2002
2	Neoplasms (Cancer) 12/2020 - 01/2020
2	Down Syndrome (Down's Syndrome) 01/2017 - 01/2013
2	Trisomy (Trisomies) 01/2017 - 01/2013
2	Retinoblastoma (Glioblastoma, Retinal) 01/2009 - 08/2006
1	Glioblastoma (Glioblastoma Multiforme) 12/2020
1	Carcinogenesis 11/2020
1	Neuroinflammatory Diseases 01/2017
1	Gliosis 01/2017
1	Intellectual Disability (Idiocy) 01/2013
1	Amyloid Plaque 01/2009
1	Hyperammonemia 03/2004
1	Mitochondrial Diseases (Mitochondrial Disease) 04/2002
1	Necrosis 04/2002

Drug/Important Bio-Agent (IBA)

6	Connexin 43 (Connexin43)IBA 08/2021 - 08/2006
6	Proteins (Proteins, Gene)FDA Link 12/2020 - 11/2010
5	Peptides (Polypeptides)IBA 08/2021 - 01/2017
3	Tolbutamide (Orinase)FDA LinkGeneric 11/2010 - 03/2005
3	Glucose (Dextrose)FDA LinkGeneric 11/2006 - 04/2002
2	Transcription Factors (Transcription Factor)IBA 01/2020 - 01/2012
2	Amyloid (Amyloid Fibrils)IBA 01/2018 - 01/2017
2	Oleic Acid (Oleate)IBA 01/2017 - 01/2013
2	Adenosine Triphosphate (ATP)IBA 11/2010 - 04/2002
2	BucladesineIBA 08/2006 - 03/2005
2	Free RadicalsIBA 04/2002 - 01/2002
1	ConnexinsIBA 01/2020
1	Cell-Penetrating PeptidesIBA 01/2020
1	NestinIBA 01/2020
1	Glial Fibrillary Acidic ProteinIBA 01/2017
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2017
1	Phosphatidylcholines (Phosphatidylcholine)IBA 01/2017
1	Serum AlbuminIBA 01/2017
1	EnzymesIBA 08/2016
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 08/2016
1	Choline O-Acetyltransferase (Choline Acetyltransferase)IBA 01/2013
1	Biological ProductsIBA 01/2013
1	PotassiumIBA 11/2010
1	KATP ChannelsIBA 11/2010
1	CyclinsIBA 01/2009
1	Amyloid beta-PeptidesIBA 01/2009
1	Small Interfering RNA (siRNA)IBA 08/2006
1	HexokinaseIBA 03/2005
1	Deoxyglucose (2 Deoxy D glucose)IBA 03/2005
1	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2004
1	AntioxidantsIBA 03/2004
1	AmmoniaIBA 03/2004
1	Glutathione (Reduced Glutathione)IBA 04/2002
1	NADP (NADPH)IBA 04/2002
1	dihydrorhodamine 123IBA 04/2002
1	Superoxides (Superoxide)IBA 04/2002
1	Oxygen (Dioxygen)IBA 04/2002
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2002

Therapy/Procedure

3	Therapeutics 12/2020 - 11/2010
1	Injections 01/2017